Prothena Corporation plc (FRA:0PT)

Market Cap	412.13M -46.0%
Revenue (ttm)	8.25M -92.8%
Net Income	-207.89M
EPS	-3.86
Shares Out	n/a
PE Ratio	n/a
Forward PE	12.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	40
Open	7.55
Previous Close	7.60
Day's Range	7.55 - 7.55
52-Week Range	3.86 - 15.20
Beta	n/a
RSI	47.73
Earnings Date	Feb 19, 2026

About Prothena Corporation

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson’s disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potent...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 163
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0PT

Financial Performance

In 2025, Prothena Corporation's revenue was $9.68 million, a decrease of -92.83% compared to the previous year's $135.16 million. Losses were -$244.09 million, 99.6% more than in 2024.

Financial numbers in USD